Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence

Autor:	Nicholas J. Talley, János Banai, Juris Pokrotnieks, M. M. Diez Alonso, Rifaat Safadi, J. Derova, Zsolt Tulassay, I. Bunganic, J. Kondrackiene, T. Vich, Salam Zakko, J. Mäkelä, Ralf Mohrbacher, Karin Dilger, Wolfgang Kruis, D. Tuculanu, N. Ferreira, Roland Greinwald, Austin Curtin, Milan Lukas, S. Björck, T. Eisenbach, Andrey E. Dorofeyev, Vassilios Kardalinos, Robin C. Spiller
Rok vydání:	2017
Předmět:	Male medicine.medical_specialty Randomised Clinical Trial Placebo Gastroenterology law.invention 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Double-Blind Method Mesalazine Randomized controlled trial Recurrence law Internal medicine parasitic diseases medicine Clinical endpoint Humans Pharmacology (medical) In patient Mesalamine Adverse effect Diverticulitis Hepatology business.industry Anti-Inflammatory Agents Non-Steroidal Middle Aged medicine.disease Surgery Clinical trial Treatment Outcome chemistry 030220 oncology & carcinogenesis Female 030211 gastroenterology & hepatology business
Zdroj:	Alimentary Pharmacology & Therapeutics
ISSN:	0269-2813
DOI:	10.1111/apt.14152
Popis:	SummaryBackground Previous studies have reached conflicting conclusions regarding the efficacy of mesalazine in the prevention of recurrent diverticulitis. Aim To investigate the efficacy and safety of mesalazine granules in the prevention of recurrence of diverticulitis after acute uncomplicated diverticulitis. Methods Two phase 3, randomised, placebo-controlled, double-blind multicentre trials (SAG-37 and SAG-51) investigated mesalazine granules in patients with prior episodes (1 episode. Safety data revealed no new adverse events. Conclusion Mesalazine was not superior to placebo in preventing recurrence of diverticulitis.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::800b5f2dc75ec3f1c8b45e31e2fde597 https://doi.org/10.1111/apt.14152 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.